Published in final edited form as:

Biochem Pharmacol. 2011 December 15; 82(12): 1919–1929. doi:10.1016/j.bcp.2011.09.009.

High density micromass cultures of a human chondrocyte cell line: A reliable assay system to reveal the modulatory functions of pharmacological agents

K.V. Greco^{c,*}, A.J. Iqbal^c, L. Rattazzi^c, G. Nalesso^c, N. Moradi-Bidhendi^c, A.R. Moore^a, M.B. Goldring^b, F. Dell'Accio^c, and M. Perretti^{c,*}

^aUCB Celltech, Slough, United Kingdom

^bResearch Division, The Hospital for Special Surgery, Weill Cornell Medical College, New York, NY 10021, USA

^cWilliam Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, United Kingdom

Abstract

Osteoarthritis is a highly prevalent and disabling disease for which we do not have a cure. The identification of suitable molecular targets is hindered by the lack of standardized, reproducible and convenient screening assays. Following extensive comparisons of a number of chondrocytic cell lines, culture conditions, and readouts, we have optimized an assay utilizing C-28/I2, a chondrocytic cell line cultured in high-density micromasses. Utilizing molecules with known effects on cartilage (e.g. IL-1 β , TGF β 1, BMP-2), we have exploited this improved protocol to (i) evoke responses characteristic of primary chondrocytes; (ii) assess the pharmacodynamics of gene over-expression using non-viral expression vectors; (iii) establish the response profiles of known pharmacological treatments; and (iv) investigate their mechanisms of action. These data indicate that we have established a *medium-throughput* methodology for studying chondrocyte-specific cellular and molecular responses (from gene expression to rapid quantitative measurement of sulfated glycosaminoglycans by Alcian blue staining) that may enable the discovery of novel therapeutics for pharmacological modulation of chondrocyte activation in osteoarthritis.

Keywords

IL-1 β ; TGF β 1; Micromasses; Anti-inflammatory drugs; Naproxen; Prednisolone

1. Introduction

Osteoarthritis (OA) is a leading cause of disability worldwide, affecting up to 2/3 of the population over 50 years of age. With incidence rates increasing with age and higher life expectancies, OA economic and social burden is ever increasing [1]. To date, a cure for osteoarthritis is not yet available though it is accepted that chondroprotection and cartilage

© 2011 Elsevier Inc. All rights reserved.

*Corresponding authors at: Centre for Biochemical Pharmacology, William Harvey Research Institute, Charterhouse Square, London, EC1M 6BQ, United Kingdom. Tel.: +44 0 20 7882 8783; fax: +44 0 20 7882 6076. k.v.greco@qmul.ac.uk (K.V. Greco), m.perretti@qmul.ac.uk (M. Perretti).

Conflict of interest

Authors declare no conflict of interest.

regeneration would represent a successful strategy, if applied early enough, and chondrocytes present an attractive target for therapeutic intervention.

Chondrocytes are responsible for the synthesis and balance of the extracellular matrix (ECM) that confers tensile strength and flexibility to articular surfaces. ECM is formed by several specific macromolecules including collagen type II [2], aggrecan core protein coated with highly sulfated glycosaminoglycans (GAG) and several other smaller structural and non-structural proteins [3]. Chondrocytes are responsible for maintaining the homeostasis of cartilage and of the ECM through a low turnover state of equilibrium between synthetic activity and catabolic remodeling mediated by specific enzymes including aggrecanases (ADAMTS family) and matrix metalloproteinases (MMPs) [4]. A loss of this homeostatic equilibrium results in the destruction of articular cartilage, which is characteristic of OA [5]. With an ever-increasing understanding of the molecular processes involved in cartilage degradation and the availability of large collections of small biologically active compounds and/or suitable macromolecules, the development of high/medium throughput assays for the identification of therapeutic molecules for chondroprotection is a priority in modern medicine. Primary cultures of adult human articular chondrocytes (AHAC) have several shortcomings for screening assays. Firstly, sample availability often represents a problem and, furthermore, there is an issue linked to donor variability that might reflect genetic factors, co-morbidity, lifestyle and more. Secondly, within the same donor there is a large variability deriving from the donor site, and also from OA being a focal disease. Thirdly, culture expansion of primary AHACs is associated with a loss of phenotype and biological behavior introducing, on the one hand, a further element of variability and, on the other, further complexity in obtaining a sufficient number of authentic chondrocytes suitable for screening purposes [6]. Finally, primary AHACs are difficult to transfect with sufficient efficiency. The recent availability of immortalized human chondrocytic cell lines [7] represents a potential solution to some of these problems. Following comparison of different cell lines and culture conditions, we establish C-28/I2 cell line in micromass cultures [8] as optimal to test the ability of different modalities of therapeutic intervention (from drugs to gene delivery) to influence chondrocyte metabolism.

2. Material and methods

2.1. Monolayer and micromass cultures of chondrocytic cell lines

The chondrosarcoma cell lines: JJO12 (kindly provided by Dr. Joel Block, Rush Medical College, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL) [9] and H-EM-SS (extraskeletal myeloid chondrosarcoma; European Collection of Animal Cell Cultures; Salisbury, UK); and the immortalized C-28/I2 cell line [8] were selected for study and compared using the same culture conditions.

Cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 (1:1; Gibco-Invitrogen, Eggenstein, Germany) supplemented with 10% fetal calf serum (FCS; Gibco-Invitrogen), 100 units/mL penicillin, and 50 µg/mL streptomycin (Omega Scientific, Tarzana, CA) (growth medium) and maintained in the presence of 5% CO₂ in air. The medium was changed every 3 days. Cells were cultured in monolayer ($2 \times 10^4/\text{cm}^2$), grown to sub-confluence (around 80% confluent) and passaged at a ratio of 1:8.

For micromass cultures, the protocol described by De Bari et al. [10] using human periosteum-derived cells was employed, with some modifications. Briefly, confluent monolayer cultures of chondrocyte cell lines were released by trypsin-EDTA, tested for viability by trypan blue exclusion, and re-suspended in growth medium at a density of 2.5×10^7 viable cells/mL. Micromasses were obtained by pipetting 20 µL of cell suspension into individual wells of 24-well plates. Following a 3-h attachment period without medium, the

growth medium was gently added and cultures left resting for a further 24 h. The medium was then changed to serum-free and phenol red-free medium (Gibco BRL) for 24 h (Supplementary data Fig. 1). Differentiation was promoted by serum starvation and ITS supplementation as described [11,12]. On day 3 of the culture, fresh differentiation medium was added and treatments were performed as described in the results. After 48 h, some of the micromasses were harvested for Alcian blue matrix staining and others for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) gene expression analysis of marker genes for chondrocytes: type II collagen alpha-1 (*COL2A1*), aggrecan (*ACAN*), sex determining region (SRY)-box 9 (*SOX9*), matrix metalloproteinase-1 and -13 (*MMP1*, *MMP13*), and a disintegrin and metalloproteinase with a thrombospondin type 1 motif 5 (*ADAMTS5*), as described in the section 2.6.

2.2. Cell proliferation assay

Cells were counted with a Neubauer hemacytometer and plated at different densities in phenol red- and serum-free medium. The top cell density was 8×10^4 , and subsequent serial dilutions (1:2, 1:4 and 1:8 1:16) were made; thus, various concentrations of cells were then seeded in triplicate in a 48-well plate ($400 \mu\text{L well}^{-1}$) and incubated in 5% CO_2 at 37 °C. After an initial 4 h period to allow cell attachment, 40 μL of alamar blue solution (Alamar, Sacramento, CA) was directly added to the medium resulting in a final concentration of 10% and the cell were returned to incubation for 24 h. The absorbance, presented as mean optical density (O.D.), of test and control wells was read after 24 h at 570 and 595 nm with a standard spectrophotometer [Spectronic 2000 spectrophotometer (Bausch & Lomb, Rochester, NY)].

2.3. Cartilage harvest and primary adult human articular chondrocyte (AHAC) isolation

AHACs were obtained with informed consent from patients who underwent joint replacement for knee OA. Cartilage samples were provided by Mr P. Achan (Barts and the London National Health Service Trust, London, UK). All procedures were approved by the East London and The City Research Ethics Committee 3. Cartilage tissue was dissected from preserved areas of the femoral condyles and the patellar groove, as recently reported [13]. Briefly, cartilage was sliced full thickness, excluding the mineralized cartilage and the subchondral bone and initially washed twice in high-glucose DMEM (DMEM/F-12 1:1 plus GlutaMax; Invitrogen, Eggenstein, Germany) containing 10% FBS, 1 mM sodium pyruvate and 2% antibiotic antimycotic solution (Invitrogen, Eggenstein, Germany). Chondrocytes were isolated from the cartilage samples by enzymatic digestion with 1 mg/mL pronase (Roche, Welwyn, UK) for 30 min at 37 °C and then overnight at 37 °C with 1 mg/mL collagenase P (Roche, Welwyn, UK) prepared in complete medium (same composition as above, with 1% antibiotic/antimycotic solution) under agitation. The AHACs recovered from the digestion were then resuspended in complete media, assessed for cell viability using trypan blue, and seeded at a density of 10,000 cells/ cm^2 . The cells were cultured at 37 °C in a humidified atmosphere containing 5% CO_2 . Only cells obtained from samples with a histological Mankin score <4 for features of OA were used for subsequent experiments [14,15]. All experiments were performed using freshly isolated or confluent P0 cells, cultured either in monolayer or micromasses.

2.4. Alcian blue (AB) staining in vitro

For semi-quantitation of cartilage-specific sulfated glycosaminoglycans, we used a protocol optimized by De Bari et al. [16], based on staining with AB 8GS at pH 0.2, which is highly specific for cartilage ECM [10,16]. Micromasses were rinsed twice with PBS, fixed with 4% glutaraldehyde solution (v/v in distilled water) for 15 min at room temperature (RT), washed with 200 μL of 0.1 N HCl (Sigma, St. Louis, MO, USA) solution in distilled water, and

covered with AB dye at pH < 1 (1% Alcian blue 8 GS in 0.1 N HCl; Carl Roth, Karlsruhe, Germany) at RT. Cultures were then washed extensively with distilled water, prior to extraction with 200 μ L of 6 M guanidine HCl (Sigma–Aldrich, St. Louis, Mo, USA) overnight at RT. The optical density (OD) of the extracted dye was measured at 630 nm using a Spectronic 2000 spectrophotometer (Bausch & Lomb, Rochester, NY, USA), and OD values were interpolated with an AB standard curve (from 625 to 9.76 μ g/ mL). Protein content for each sample was determined using the BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Initially, the amount of extracted AB was normalized with protein content and expressed as AB/protein (μ g/ μ g), such as in the experiments where cell lines and primary AHAC were compared (Supplementary data Fig. 2). In all other assays, GAG accumulation was measured by AB quantification and normalized to DNA content (μ g/ μ g), as described below.

2.5. DNA quantification

DNA content was measured by fluorescence using SYBR Green I dye (Invitrogen, Paisley, UK). For each micromass sample, DNA concentration was assessed against a DNA standard curve [dsDNA for Standard Curve–Lambda DNA (Invitrogen, Paisley, UK)] after preparation in an assay solution [10 mM Tris–HCl, 1 mM EDTA, pH8, containing 1% (v/v) of SYBR Green I dye]. DNA samples were diluted (1:50), homogenized with the assay solution (1:20), measured at 485/535 nm by using a spectrophotometer (TECAN-M200; Tecan, Männedorf, Switzerland). These values were used to normalize GAG concentrations.

2.6. Aggrecan protein detection by Western blotting

Micromasses were washed and lysed with cold lysis buffer [20 mM Tris–HCl pH 8, 137 mM NaCl, 1% (v/v), Nonidet P-40, 2 mM EDTA] supplemented with protease inhibitors and sodium vanadate (both in a dilution of 1:100). Cell lysates were centrifuged at 15,000 $\times$ g for 15 min and the supernatants were recovered. Protein samples were subjected to SDS–polyacrylamide gel electrophoresis using a 10% (w/v) gel. Proteins were blotted to polyvinylidene difluoride membranes (PVDF; Millipore, Watford, UK) and blocked for 1 h on a plate rocker in either 5% (w/v) BSA or 5% milk solution (w/v) in Tris-buffered saline (TBS) (150 mM sodium chloride, 2 mM Tris base, pH7.4) containing 0.1% Tween 20 (Sigma) (TBS-T). Aggrecan was detected following overnight incubation at 4 °C, on a plate rocker in TBS-T with primary Ab; a rabbit polyclonal antibody (GeneTex, Inc., USA) diluted 1:1000 in PBS containing 5% (w/v) nonfat dry milk. The following day, membranes were incubated for 1 h at RT with the secondary antibody [donkey anti-rabbit IgG (1:4000; Amersham Biosciences, Amersham, UK)]. Membranes were re-probed with monoclonal mouse anti-human β -actin (dilution 1:10,000 in 5% milk solution, clone AC-15, Sigma). Proteins were detected using the ECL Detection Kit and visualized on Hyperfilm (Amersham Biosciences, Amersham, UK). Densitometry was performed using ImageJ software analysis. The value from each band was subtracted from background values, and the protein band was normalized against β -actin as detected in the same sample.

2.7. Real-time PCR

Total RNA was extracted using a commercially available kit (Qiagen RNeasy Mini Kit; Qiagen, Hilden, Germany), according to the manufacturer's instructions. The concentration and purity of the RNA was analysed using the Nandrop ND-1000 (NanoDrop Technologies, Wilmington, DE). Complementary DNA (cDNA) were obtained by reverse transcription (RT) of 2 μ g of total RNA, with the Superscript III reverse transcriptase system (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol and using oligo(dT)₁₅ as primer. Real-time PCR was performed with the ABI Prism 7900 Real-time PCR system (Applied Biosystems Inc., CA, USA). The following amplification profile was used: 95 °C for 15

min; 35 cycles- 94 °C for 15 s, 55 °C for 30 s and 72 °C for 30 s, followed by a melt curve analysis. For each reaction, a total volume of 10 µL was used, which consisted of 2 µL of diluted cDNA (10 ng/ µL of RNA), 5.2 µL of 1× Power SYBR Green mastermix (Applied Biosystems, Inc., CA, USA), 1.8 µL of dH₂O, and 1 µL of gene specific primer. Commercially available primers (Qiagen, West Sussex, UK) were used to probe for target mRNA (Hs_SOX9, QT00001498; Hs_COL2A1, QT00049518; Hs_ACAN, QT00001365; Hs_MMP1, QT 00014581; Hs_MMP13, QT00001764; Hs_ADAMTS5, QT00011088; Hs_GAPDH, QT01192646; and Hs_BMP2, QT00012544). mRNA data were normalized relative to GAPDH and then used to calculate expression levels. The comparative Ct method was used to measure the gene transcription in samples [17]. Results are expressed as relative units based on calculation of $2^{-\Delta\Delta C_t}$, which gives the relative amount of target gene normalized to endogenous control (GAPDH) and to the control (untreated) samples with the expression set as 1. Negative controls were either RT without enzyme or PCR without cDNA template.

2.8. Quantification of PGE₂ levels

The PGE₂ concentrations in cell culture supernatants were measured using a specific enzyme immunoassay kit (Cayman Chemical Co., Ann Arbor, MI, USA) according to the manufacturer's recommendation (sensitivity of 9 pg/mL). All assays were performed in triplicate.

2.9. Transfection of C-28/I2 cells

Transient transfection experiments were carried out in C-28/I2 chondrocytes in monolayer using the lipid-based transfection reagent FuGene6 (Transfection Reagent; Roche Molecular Biochemical, Indianapolis, IN, USA). The human BMP-2 plasmid (pMT7T3-BMP2) was a gift from Dr Gerhard Gross (Helmholtz Centre for Infection Research, Braunschweig, Germany). Cell number was determined by hemocytometry. Viability, as determined by trypan blue exclusion, always exceeded 90%. Cells were cultured in monolayers in 6-well plates at 2.5×10^4 cells/cm² in medium containing 10% fetal bovine serum; transfection experiments were performed at sub-confluence (density 60–70%). The pMT7T3-BMP2/ Fugene or EGFP (control) complexes were added in a dropwise fashion to the cell cultures. Following preliminary experiments, optimal transfection efficiency was obtained with 3 µg DNA and 9 µL of Fugene or with a ratio DNA/Fugene of 3:3 (w/ v), using 8 h exposure. After incubation at 37 °C, bright field and fluorescent images were taken of the cultures transfected with the control (EGFP) and the percentage of transfected cells was calculated. The cells were harvested and resuspended in a 2.5×10^7 cells/mL to establish micromass cultures. Using GFP-vector, a transfection efficiency of $30 \pm 3\%$ with 95% viability could be calculated.

2.10. Statistical analysis

All data are reported as mean $\pm$ SD of n observations, and were performed in duplicate and repeated at least three times. Statistical evaluation was performed using one-way analysis of variance (ANOVA) (Prism4 GraphPad Software, San Diego, USA) followed by Bonferroni test for post hoc analyses. When two experimental groups were compared, a Student's *t*-test was used. In all cases, a probability *p* value ≤ 0.05 was taken as significant.

3. Results

3.1. Selection of C-28/I2 cells for micromass cultures

One aim of this study was to establish a rapid and reproducible screening assay for chondroprotective molecules and anti-inflammatory drugs. We began by comparing several

human chondrocytic cell lines for their growth rate and differentiation markers. H-EMC-SS displayed a gene expression profile of a chondrocytic cell line in monolayer (*SOX9* mRNA expression is almost 50% increased when compared to C-28/I2) (Fig. 1A), yet these cells had slow proliferation rates when compared to JJO12 and C-28/I2 lines (Fig. 1B). The latter two cell lines showed similar proliferation rates (Fig. 1B); however our choice fell on the C-28/I2 human chondrocyte cell line because of the combination of a suitable growth rate and a gene profile of phenotypic markers which resembles more closely that of primary adult human articular chondrocytes (AHACs) (Fig. 1A).

When compared to primary AHACs, the C-28/I2 cells displayed an overall lower expression of phenotypic marker genes (*SOX9*, *COL2A1*, *ACAN*, *MMP1*, *MMP13* and *ADAMTS5*) upon culture in monolayer (Fig. 1A), associated with lower accumulation of highly sulfated glycosaminoglycans as measured by Alcian blue staining and spectrophotometric quantification (Supplementary Fig. 2). However, when compared to the other cell lines tested in this study, C-28/I2 cells in micromass displayed enhanced expression of chondrocyte marker genes (with significant up-regulation in *SOX9*, *COL2A1* and *ACAN* mRNA; Supplemental Table 1) and slightly increased accumulation of GAG-rich proteins (Supplemental Fig. 2). Thus, the C-28/I2 cell line cultured in high-density micromass was selected for further analyses.

3.2. C-28/I2 cells in micromass respond to anabolic and catabolic stimuli

Treatment of micromasses with TGFβ1 induced significant up-regulation of cartilage phenotypic markers (*SOX9*, *COL2A1*, *ACAN*), with down-regulation of the catabolic (*MMP13* and *ADAMTS5*) gene products (Fig. 2E). This was mirrored by an augmented accumulation of GAG-rich extracellular matrix *in vitro* (Fig. 2A) reflected by higher values for AB extraction (Fig. 2B). These ECM-related responses were paralleled by TGFβ1-enhanced aggrecan protein expression as assessed by Western blot (Fig. 2C and D).

In contrast, treatment of these micromasses with catabolic signal IL-1β led to a significant ~50% reduction in GAG content (Fig. 2A and B) and aggrecan protein blotting (Fig. 2C and D). Gene expression responses to the anabolic and catabolic stimuli of C-28/I2 cells cultured in micromasses were qualitatively similar (Fig. 2E), though not so marked in their degree, to that measured with primary AHACs (Fig. 2F).

Next, we tested whether C-28/I2 cells could be amenable to gene transfection studies. Using the Fugene[®]6 protocol, an efficiency of ~30% could be determined, as evaluated by counting fluorescent cells following transfection with control EGFP plasmid. The cells remained EGFP-positive after 7 days of culture (some transfected cells were kept up to 10 days for verification purposes). Transfection efficiency did not result from any significant change in cell viability, which remained well over 95% (Table 1). When the pMT7T3-BMP2 vector was transfected, C-28/I2 cells responded with a marked accumulation of sulfated GAGs (Fig. 3A and Table 1) which was, again, associated with the expected changes in the anabolic gene markers *SOX9*, *COL2A1* and *ACAN*, with ~3-fold, >12-fold and ~6-fold increase, respectively (Fig. 3B). Of note was the up-regulation (~4-fold increase) observed on BMP-2 mRNA after BMP-2 transfection (Fig. 3B).

Effect of prototypical anti-inflammatory drugs on C-28/I2 micromass responses. Finally we determined whether this cell culture assay, could be applied to reveal chondroprotective properties of pharmacological molecules and to do so we tested naproxen (NAP), prototype of cyclo-oxygenase inhibitors, and prednisolone (PRED), prototype of clinically relevant glucocorticoids. In resting C-28/I2 micromass cultures, treatment with PRED (10–1000 nM) and NAP (1–100 μM) for 48 h did not alter the accumulation of GAG (Fig. 4A), nor was there any change observed in mRNA levels of anabolic genes following treatment with

PRED (Table 2). However, NAP reduced *COL2A1* and *ACAN* mRNA levels by approximately 30% (Table 2).

In the presence of catabolic stimulation by IL-1 β , NAP inhibited the accumulation of GAG-rich proteins without returning values back to basal levels (Fig. 4A). Nevertheless, NAP produced a marked attenuation of IL-1 β -induced *MMP1* and *MMP13* mRNA expression (e.g., >60% inhibition on *MMP13*) (Fig. 4C). No beneficial effect on anabolic gene expression could be detected. Additionally, no modulation of *ADAMTS5* was observed following treatment with this cyclooxygenase inhibitor.

The glucocorticoid PRED prevented the catabolic effect of IL-1 β on GAG content, with significantly enhanced responses through all tested concentrations (Fig. 4A). The anti-catabolic effect of PRED was underpinned by strong inhibition of all three proteolytic enzyme genes: *MMP1*, *MMP13* and *ADAMTS5* mRNA levels were decreased by over 60% (Fig. 4B). Moreover, *COL2A1* mRNA expression was also up-regulated.

To gain further notion on the modulation of cell responses by NAP and PRED, we measured the production of PGE₂ in the supernatants of micromasses. NAP afforded significant reductions at all concentrations tested, in the presence or absence of IL-1 β (Table 3). In contrast to NAP, PRED did not significantly modulate PGE₂ production (Table 3), leaving open the possibility of other chondroprotective mechanisms, which need to be further investigated. Based on these results, we selected 10 μ M NAP and 0.1 μ M PRED for testing on primary chondrocytes to challenge the predictive value of the C-28/I2 micromass-culture assay.

Primary AHAC in micromass were stimulated with IL-1 β in the presence or absence of the two pharmacological tools for 48 h. As shown in Fig. 5, both NAP and PRED abrogated the effects of IL-1 β on the catabolic enzyme gene expression profile, e.g. *MMP13* and *ADAMTS5*, but only PRED displayed modest effects on anabolic genes, as indicated by the up-regulation of *SOX9* (Fig. 5A) and *ACAN* (Fig. 5C) mRNA expression.

Altogether the results with primary chondrocytes were, at least qualitatively, similar to those obtained with C-28/I2 micromass cultures, depicting NAP and PRED modulation of cell reactivity to a similar degree, though not necessarily to a similar extent.

4. Discussion

In this study, we describe a reliable culture assay using a chondrocytic cell line, providing strong evidence for its utility to reveal anabolic and catabolic responses, including those induced by gene transfection, as well as to investigate the properties of chondroprotective and anti-inflammatory drugs. Use of primary chondrocytes afforded strong proof-of-concept for the validity and relevance of a chondrocyte cell line that we chose for characterization in the micromass culture system.

Primary adult human articular chondrocytes (AHACs) cultures constitute an attractive tool for investigating intracellular and molecular features of chondrocyte differentiation and activation [18]. However, during assessments of phenotype and responsiveness to stimuli [7], marked variability between cells from different donors or even between different areas of the same joint can produce artifacts that bias results and lead to limited experimental analysis. Hence, better strategies for using chondrocyte cell lines are remarkably required [4,19].

We began this study by comparing the growth rates and gene expression profiles of three well-known human chondrocytic cell lines in different culture conditions. We selected the

chondrosarcoma cell lines JJO12 [20,21] and H-EMC-SS [22], and the immortalized chondrocytes, C-28/I2 [7,8] and compared their behavior in monolayer and micromass cultures. Selected readouts were expression profiles of genes involved in matrix production (*COL2A1* and *ACAN*) [3], and *SOX9*, a pivotal transcriptional regulator that is essential for chondrocyte differentiation [23]. As catabolic markers, we selected: *MMP13*, the major type II collagen-degrading collagenase, known to be regulated by stress-, inflammation-, and differentiation-induced signals [24], *MMP1* [25], and the main aggrecanase involved in matrix degradation, *ADAMTS5* [26,27].

In monolayer, all analysed cell lines showed only very limited similarities in gene expression of cartilage differentiation markers compared to primary AHAC. Nevertheless, we selected the C-28/I2 cells for their rapid growth rate combined with a relatively better chondrocyte-like phenotype, compared to other cell lines, in micromass culture. The results obtained in this study are in line with the known positive effects of high-density cultures on the phenotypic profile of primary cells [11,28–32]. In accordance with the literature, this protocol yielded high *SOX9* gene expression, the principle phenotypic marker of chondrocytes [33], and associated changes in *COL2A1* and *ACAN*, genes involved with cartilage-specific ECM.

Interestingly, C-28/I2 in micromasses expressed higher levels of genes associated with matrix degradation (*MMP1* and *ADAMTS5*), which has also been detected in primary AHAC in high-density cultures [28]. This suggests that this cell line might be a good option to investigate not only matrix anabolism but also catabolism in chondrocytic cells [7]. Other advantages of the micromass system using cell lines include its rapidity and simplicity, allowing rapid screenings to measure accumulation of GAG-rich extracellular matrix by Alcian blue staining. AB binds to anionic groups on highly sulfated GAG [34,35] and, at low pH values, selectively stains cartilage-specific matrix [16].

One important aspect of this study is the retrospective validation of the detection of bioactive agents that have been proven to be active *in vivo*. In spite of its relatively simplicity, this system proved to be sensitive to agents that are known to be either catabolic or anabolic for chondrocytes *in vivo*, such as IL-1 β [36,37] and TGF β 1 [38,39], respectively. Application of these two chondrocyte stimuli yielded the expected modulation of C-28/I2 responsiveness, which was strictly reflected in the amount of AB staining. The patterns of relative mRNA expression of chondrocyte marker genes in C-28/I2 cells upon TGF β 1 and IL-1 β stimulation were also clearly comparable with the results produced with primary AHAC, giving confidence for this protocol as an alternative to assays based upon primary cells.

Finally, we postulated another advantage of this cell line over the primary cells, which is its potential use for gene transfection studies, as primary AHAC are resistant to most transfection methods and consequently not amenable to *high-throughput* mechanistic studies to screen the consequences of gene over-expression [40]. To this end, we used a plasmid vector to overexpress BMP-2, a pivotal anabolic molecule that can increase *COL2A1* and *ACAN* gene expression and is induced by cytokines in articular chondrocytes [41,42].

C-28/I2 cells could be transfected to approximately 30% and yet produce viable micromasses, as evident following transfection with the control EGFP-positive plasmid. Transfection with human pMT7T3-BMP2 plasmid yielded an up-regulation of BMP-2 mRNA, as well as a selective anabolic response chiefly assessed both by AB staining and augmented *SOX-9*, *COL2A1* and *ACAN* gene expression. This response is congruent with studies showing that BMP-2 is a critical molecule in cartilage development [43] with a dramatic improvement of the chondrogenic phenotype of human articular chondrocytes [44].

Inflammation is the main pathogenic mechanism for cartilage destruction in rheumatoid arthritis and is also a major risk factor in OA [45,46]. Marked differences exist among anti-inflammatory drugs with respect to their ability to modulate inflammation in the joint; their capacity to modulate proteases and inhibitors is unproven, suggesting a requirement for new approaches to study their actions on chondrocytes [47–49].

We have therefore assessed the effects of two compounds that are known to counteract inflammation: the glucocorticoid prednisolone (PRED), and naproxen (NAP), a non-selective cyclo-oxygenase inhibitor [50,51]. In line with published data produced using primary chondrocytes or human explants [52–55], addition of NAP decreased the IL-1 β -induced catabolic activity on chondrocytes, however, no further effect on ECM protein accumulation was observed [56]. The more evident effect of NAP in counteracting IL-1 β -elicited catabolic responses was in down-regulating matrix metalloproteinases (*MMP*)-1 and 13 mRNA. It has been reported in the literature that NAP decreases MMPs and this effect may be in part addressed to its positive effect on tissue inhibitors of metalloproteinases, which form inhibitory complexes with MMPs in a 1:1 stoichiometry [48,55].

Our results using NAP are at variance with those using PRED; addition of this drug to micromasses did not elicit detectable responses on its own, but profoundly affected IL-1 β -elicited responses in terms of AB staining, which could be correlated with marked down-regulation of expression of the most potent matrix degradative protease *ADAMTS5*, as well as both *MMP1* and *MMP13*. At high concentrations, PRED could fully overcome the suppression of anabolism by IL-1 β with higher expression of *COL2A1* and augmented AB staining.

It is interesting to note how NAP and PRED effects on C-28/I2 cell reactivity to IL-1 β was replicated with primary chondrocytes, satisfying the notion that this high-density culture system using this chondrocytic cell line can be predictive of chondrocyte biological responses and their modulation by therapeutic treatments. We propose that this assay can be run as a medium-throughput screening system for anti-inflammatory and chondroprotective drugs.

Mechanistically, we showed that the effects of NAP were related to the inhibition of PGE₂ synthesis and release. Although the biologic activities of this prostaglandin in articular cartilage have sparked controversy [57–59], it appears to be protective in chondrocytes [60,61], increasing anabolic activity in OA cartilage [62,63]. At this level, cytokine-induced synthesis of PGE₂ is part of a circuit that positively regulates *COL2A1* transcription [64]. The protective role of PGE₂ on chondrocytes could be indirectly confirmed by this study, as NAP reduced expression of genes involved in matrix production (*COL2A1* and *ACAN*) in resting conditions, which in part may be due to a reduction of PGE₂ production. Moreover at higher doses of NAP, both PGE₂ and anabolic gene expression were reduced, highlighting the impact of NAP as a suppressive compound in chondrocyte biology.

Our data also indicate a profound inhibition of PGE₂ levels by NAP upon IL-1 β stimulation, which has been reported previously [65]. We confirmed and also demonstrated that this effect on PGE₂ correlates with no change in the phenotypic genes related to ECM synthesis, since a similar degree of expression was observed following stimulation with IL-1 β or NAP treatment. The inhibitory effect on chondrocyte metabolism exerted by NAP was also highlighted in this study by using primary chondrocytes. Although this observation has been demonstrated only in short-term *in vitro* studies, it may be clinically relevant, as nonsteroidal anti-inflammatory drugs have been used often to relieve symptoms of OA patients; however, they may also potentially affect cartilage repair in these circumstances [66,67].

Controversially, the potential mechanism(s) behind the beneficial effect of PRED on chondrocytes are clearly independent from any effect on PGE₂ levels, opening the possibility that other downstream regulators of glucocorticoids could be operative in these settings, including Annexin A1, dual-specificity phosphatase-1 or macrophage-inflammatory factor [68,69]. In initial analyses we have observed high Annexin A1 gene expression in C-28/I2 cells (Greco and Dalli, not shown), however its potential involvement in the observed actions of PRED is still to be verified.

In summary, high-density micromass cultures of a human chondrocytic cell line represent a reliable experimental tool to test strategies that might interfere with matrix synthesis and degradation. The biological effects of BMP-2 overexpression, and pharmacological application of NAP and PRED allow us to propose the potential for this system to unveil novel chondroprotective molecules; in addition, such human chondrocyte micromasses could also be used to study the impact of pathogenic circuits with the potential of shedding light on mechanism relevant to OA, hence suitable for testing novel therapeutic approaches.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr Gerhard Gross (Department of Molecular Biotechnology, Signaling and Gene Regulation, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany), who kindly provided the BMP-2 plasmid. We also thank Dr Joel Block (Rush Medical College, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL) who kindly provided the JJO12 chondrosarcoma cell line.

Financial support: This work was supported by a collaborative project between UCB (Slough, United Kingdom) and the William Harvey Research Foundation (London, United Kingdom). Dr. Goldring's research is supported by National Institutes of Health, Grant R01-AG022021.

References

1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis Rheum.* 2008; 58(1):26–35. [PubMed: 18163497]
2. Poole AR, Kobayashi M, Yasuda T, Lavery S, Mwale F, Kojima T, et al. Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. *Ann Rheum Dis.* 2002; 61(2): 78–81.
3. Goldring MB. The role of the chondrocyte in osteoarthritis. *Arthritis Rheum.* 2000; 43(9):1916–26. [PubMed: 11014341]
4. Otero M, Goldring MB. Cells of synovium in rheumatoid arthritis, chondrocytes. *Arthritis Res Ther.* 2007; 9(5):220. [PubMed: 18001488]
5. Aigner T, Soeder S, Haag J. IL-1b and BMPs—interactive players of cartilage matrix degradation and regeneration. *Eur Cells Mater.* 2006; 12:49–56.
6. Dell'Accio F, De Bari C, Luyten FP. Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo. *Arthritis Rheum.* 2001; 44:1608–19. [PubMed: 11465712]
7. Finger F, Schorle C, Zien A, Gebhard P, Goldring MB, Aigner T. Molecular phenotyping of human chondrocyte cell lines T/C-28a2, T/C-28a4, and C-28/I2. *Arthritis Rheum.* 2003; 48(12):3395–403. [PubMed: 14673991]
8. Goldring MB, Birkhead JR, Suen L-F, Yamin R, Mizuno S, Glowacki J, et al. Interleukin-1-modulated gene expression in immortalized human chondrocytes. *J Clin Invest.* 1994; 94:2307–16. [PubMed: 7989586]

9. Scully SP, Berend KR, Toth A, Qi WN, Qi Z, Block JA. Interstitial collagenase gene expression correlates with in vivo invasion in human chondrosarcoma. *Clin Orthop Relat Res.* 2000; 376:291–303. [PubMed: 10906887]
10. De Bari C, Dell'Accio F, Luyten FP. Human periosteum-derived cells maintain phenotypic stability and chondrogenic potential throughout expansion regardless of donor age. *Arthritis Rheum.* 2001; 41(1):85–95. [PubMed: 11212180]
11. Kokenyesi R, Tan L, Robbins J, Goldring MB. Proteoglycan production by immortalized chondrocyte cell lines cultured under conditions that promote expression of the differentiated phenotype. *Arch Biochem Biophys.* 2000; 383:79–90. [PubMed: 11097179]
12. Chua KH, Aminuddin BS, Fuzina NH, Ruzsyzmah BHI. Insulin-transferrin-selenium prevent human chondrocyte dedifferentiation and promote the formation of high quality tissue engineered human hyaline cartilage. *Eur Cells Mater.* 2005; 9:58–67.
13. Nalesso G, Sherwood J, Bertrand J, Pap T, Ramachandran M, De Bari C, et al. WNT-3A modulates articular chondrocyte phenotype by activating both canonical and noncanonical pathways. *J Cell Biol.* 2011; 193(3):551–64. [PubMed: 21536751]
14. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical metabolic abnormalities in articular cartilage from osteo-arthritic human hips II. Correlation of morphology with biochemical and metabolic data. *J Bone Joint Surg Am.* 1971; 53:523–37. [PubMed: 5580011]
15. Dell'Accio F, De Bari C, Eltawil NM, Vanhummelen P, Pitzalis C. Identification of the molecular response of articular cartilage to injury, by microarray screening: Wnt-16 expression and signaling after injury and in osteoarthritis. *Arthritis Rheum.* 2008; 58(5):1410–21.
16. De Bari C, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheum.* 2001; 44(8):1928–42. [PubMed: 11508446]
17. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* 2001; 29:e45. [PubMed: 11328886]
18. Gosset M, Berenbaum F, Thirion S, Jacques C. Primary culture and phenotyping of murine chondrocytes. *Nat Protoc.* 2008; 3(8):1253–312. [PubMed: 18714293]
19. Goldring MB. Culture of immortalized chondrocytes and their use as models of chondrocyte function. *Methods Mol Med.* 2004; 100:37–52. [PubMed: 15280586]
20. Fong YC, Yang WH, Hsu SF, Hsu HC, Tseng KF, Hsu CJ, et al. 2-methoxyestradiol induces apoptosis and cell cycle arrest in human chondrosarcoma cells. *J Orthop Res.* 2007; 25:1106–14. [PubMed: 17415781]
21. Lai TH, Fong YC, Fu WM, Yang RS, Tang CH. Stromal cell-derived factor-1 increase avb3 integrin expression and invasion in human chondrosarcoma cells. *J Cell Physiol.* 2008; 218(2): 334–42. [PubMed: 18814143]
22. Bui C, Ouzzine M, Talhaoui I, Sharp S, Prydz K, Coughtrie MWH, et al. Epigenetics: methylation-associated repression of heparan sulfate 3-O-sulfotransferase gene expression contributes to the invasive phenotype of H-EMC-SS chondrosarcoma cells. *FASEB J.* 2010; 24:436–50. [PubMed: 19812376]
23. Lefebvre V, Smits P. Transcriptional control of chondrocyte fate and differentiation. *Birth Defects Res C Embryo Today.* 2005; 75:200–12. [PubMed: 16187326]
24. Goldring MB, Otero M, Plumb DA, Dragomir C, Favero M, El Hachem K, et al. Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in Osteoarthritis. *Eur Cells Mater.* 2011; 21:202–20.
25. Flannely J, Chambers MG, Dudhia J, Hembry RM, Murphy G, Mason RM, et al. Metalloproteinase and tissue inhibitor of metalloproteinase expression in the murine STR/ort model of osteoarthritis. *Osteoarthritis Cartilage.* 2002; 10(9):722–33. [PubMed: 12202125]
26. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active *ADAMTS5* prevents cartilage degradation in a murine model of osteoarthritis. *Nature.* 2005; 434:644–8. [PubMed: 15800624]
27. Plaas A, Osborn B, Yoshihara Y, Bai Y, Bloom T, Nelson F, et al. Aggreganolytic in human osteoarthritis: confocal localization and biochemical characterization of *ADAMTS5*-hyaluronan complexes in articular cartilages. *Osteoarthritis Cartilage.* 2007; 15:719–34. [PubMed: 17360199]

28. Dehne T, Schenk R, Perka C, Morawietz L, Pruss A, Sittinger M, et al. Gene expression profiling of primary human articular chondrocytes in high-density micromasses reveals patterns of recovery, maintenance, re- and dedifferentiation. *Gene*. 2010; 462(1–2):8–17. [PubMed: 20433912]
29. Andreas K, Haupl H, Lubke C, Ringe J, Morawietz L, Wachtel A, et al. Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. *Arthritis Res Ther*. 2009; 11(1):1–14.
30. Fedewa MM, Oegema TR Jr, Schwartz MH, MacLeod A, Lewis JL. Chondrocytes in culture produce a mechanically functional tissue. *J Orthop Res*. 1998; 16:227–36. [PubMed: 9621897]
31. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. In vitro chondrogenesis of bone marrowderived mesenchymal progenitor cells. *Exp Cell Res*. 1998; 238:265–72. [PubMed: 9457080]
32. Kato Y, Iwamoto M, Koike T, Suzuki F, Takano Y. Terminal differentiation and calcification in rabbit chondrocyte cultures grown in centrifuge tubes: regulation by transforming growth factor beta and serum factors. *Proc Natl Acad Sci USA*. 1998; 85:9552–6. [PubMed: 3200840]
33. de Crombrughe B, Lefebvre V, Behringer RR, Bi W, Murakami S, Huang W. Transcriptional mechanisms of chondrocyte differentiation. *Matrix Biol*. 2000; 19(5):389–94. [PubMed: 10980415]
34. Rosenberg L. Chemical basis for the histological use of safranin O in the study of articular cartilage. *J Bone Joint Surg*. 1971; 53A:69–82. [PubMed: 4250366]
35. Schulze-Tanzil G, Souza P, John VCT, Merker HJ, Scheid A, Shakibaei M. Redifferentiation of dedifferentiated human chondrocytes in high-density cultures. *Cell Tissue Res*. 2002; 308:371–9. [PubMed: 12107430]
36. Bertrand J, Cromme C, Umlauf D, Frank S, Pap T. Molecular mechanisms of cartilage remodeling in osteoarthritis. *Int J Biochem Cell Biol*. 2010; 42:1594–601. [PubMed: 20603225]
37. Kobayashi T, Notoya K, Naito T, Unno S, Nakamura A, Martel-Pelletier J, et al. A peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. *Arthritis Rheum*. 2005; 52(2):479–87. [PubMed: 15692987]
38. Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduction of osteophyte formation and synovial thickening by adenoviral overexpression of transforming growth factor β /bone morphogenetic protein inhibitors during experimental osteoarthritis. *Arthritis Rheum*. 2003; 48(12):3442–51. [PubMed: 14673995]
39. Glansbeek HL, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg WB. Stimulation of articular cartilage repair in established arthritis by local administration of transforming growth factor-beta into murine knee joints. *Lab Invest*. 1998; 78(2):133–42. [PubMed: 9484711]
40. Madry H, Trippel SB. Efficient lipid-mediated gene transfer to articular chondrocytes. *Gene Ther*. 2000; 7:286–91. [PubMed: 10694808]
41. Valentin-Opran A, Wozney J, Csimma C, Lilly L, Riedel GE. Clinical evaluation of recombinant human bone morphogenetic protein-2. *Clin Orthop Relat Res*. 2002; 395:110–20. [PubMed: 11937870]
42. Fukui N, Zhu Y, Maloney WJ, et al. Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF- α in normal and osteoarthritic chondrocytes. *J Bone Joint Surg Am*. 2003; 85-A(Suppl 3):59–66. [PubMed: 12925611]
43. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. *Growth Factors*. 2004; 22(4):233–41. [PubMed: 15621726]
44. Claus S, Aubert-Foucher E, Demoor M, Camuzeaux B, Paumier A, Piperno M, et al. Chronic exposure of bone morphogenetic protein-2 favors chondrogenic expression in human articular chondrocytes amplified in monolayer cultures. *J Cell Biochem*. 2010; 111:1642–51. [PubMed: 21053273]
45. Goldring MB, Goldring SR. Osteoarthritis. *J Cell Physiol*. 2007; 213:626–34. [PubMed: 17786965]
46. Krenn V, Morawietz L, Burmester GR, Kinne RW, Mueller-Ladner U, Muller B, et al. Synovitis score: discrimination between chronic low-grade and high-grade synovitis. *Histopathology*. 2006; 9:358–64. [PubMed: 16978198]

47. Bolla M, Viappiani S, Dave M, Patel J, Abramson S, Attur M. Effects of NSAIDs and the cyclooxygenase-inhibiting nitric oxide donator (CINOD) NCX 429 on human chondrocytes and cartilage from OA patients [abstract]. *Arthritis Rheum.* 2010; 62(10):1477.
48. Sadowski T, Steinmeyer J. Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes. *Osteoarthritis Cartilage.* 2001; 9(5):407–15. [PubMed: 11467888]
49. Shield MJ. Anti-inflammatory drugs and their effects on cartilage synthesis and renal function. *Eur J Rheumatol Inflamm.* 1993; 13(1):7–16. [PubMed: 7821339]
50. Morand EF. Effects of glucocorticoids on inflammation and arthritis. *Curr Opin Rheumatol.* 2007; 19(3):302–7. [PubMed: 17414960]
51. Warner TD, Mitchell JA. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs. *Lancet.* 2008; 371:270–3. [PubMed: 18207021]
52. Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP. Differential direct effects of cyclooxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. *Arthritis Res Ther.* 2006; 8(1):R2. [PubMed: 16356188]
53. Bassleer C, Herontin Y, Franchimont P. Effects of sodium naproxen on differentiated human chondrocytes cultivated in clusters. *Clin Rheumatol.* 1992; 11(1):60–5. [PubMed: 1582121]
54. Ding C. Do NSAIDs affect the progression of osteoarthritis? *Inflammation.* 2002; 26(3):139–42. [PubMed: 12083420]
55. Henrotin Y, Reginster JY. In-vitro differences among nonsteroidal anti-inflammatory drugs in their activities related to osteoarthritis pathophysiology. *Osteoarthritis Cartilage.* 1999; 7:355–7. [PubMed: 10329331]
56. Glazer PA, Rosenwasser MP, Ratcliffe A. The effect of naproxen and interleukin-1 on proteoglycan catabolism and on neutral metalloproteinase activity in normal articular cartilage in vitro. *J Clin Pharmacol.* 1993; 33(2):109–14. [PubMed: 8440758]
57. Li X, Ellman M, Muddasani P, Wang JHC, Cs-Szabo G, van Wijnen AJ, et al. Prostaglandin E2 and its cognate EP receptors control human adult articular cartilage homeostasis and are linked to the pathophysiology of osteoarthritis. *Arthritis Rheum.* 2009; 60(2):513–23. [PubMed: 19180509]
58. Miwa M, Saura R, Hirata S, Hayashi Y, Mizuno K, Itoh H. Induction of apoptosis in bovine articular chondrocyte by prostaglandin E(2) through cAMP-dependent pathway. *Osteoarthritis Cartilage.* 2000; 8:17–24. [PubMed: 10607495]
59. Attur M, Al-Mussawir HE, Patel J, Kitay A, Dave M, Palmer G, et al. Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor. *J Immunol.* 2008; 181(7):5082–8. [PubMed: 18802112]
60. Tchetina EV, Di Battista JA, Zukor DJ, Antoniou J, Poole AR. Prostaglandin PGE2 at very low concentrations suppresses collagen cleavage in cultured human osteoarthritic articular cartilage: this involves a decrease in expression of proinflammatory genes, collagenases and COL10A1, a gene linked to chondrocyte hypertrophy. *Arthritis Res Ther.* 2007; 9:R75. [PubMed: 17683641]
61. Otsuka S, Aoyama T, Furu M, Ito K, Jin Y, Nasu A, et al. PGE2 signal via EP2 receptors evoked by a selective agonist enhances regeneration of injured articular cartilage. *Osteoarthritis Cartilage.* 2009; 17:529–38. [PubMed: 18922704]
62. Goldring MB, Fukuo K, Birkhead JR, et al. Transcriptional suppression by interleukin-1 and interferon- γ of type II collagen gene expression in human chondrocytes. *J Cell Biochem.* 1994; 54:85–99. [PubMed: 8126089]
63. Goldring MB, Suen LF, Yamin R, Lai WF. Regulation of collagen gene expression by prostaglandins and interleukin-1- β in cultured chondrocytes and fibroblasts. *Am J Ther.* 1996; 3:9–16. [PubMed: 11856992]
64. Miyamoto M, Ito H, Mukai S, Kobayashi T, Yamamoto H, Kobayashi M, et al. Simultaneous stimulation of EP2 and EP4 is essential to the effect of prostaglandin E2 in chondrocyte differentiation. *Osteoarthritis Cartilage.* 2003; 11:644–52. [PubMed: 12954235]

65. Chen SH, Fahmi H, Shi Q, Benderdour M. Regulation of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase-activating protein/5-lipoxygenase by 4-hydroxynonenal in human osteoarthritic chondrocytes. *Arthritis Res Ther*. 2010; 12(1):R21. [PubMed: 20144213]
66. Dingle JT. The effects of NSAID on the matrix of human articular cartilages. *Z Rheumatol*. 1999; 58:125–9. [PubMed: 10441838]
67. Hungin APS, Kean DWF. Nonsteroidal anti-inflammatory drugs: overused or underused in osteoarthritis? *Am J Med*. 2001; 110(1):8–11.
68. Clark AR. Anti-inflammatory functions of glucocorticoid- induced genes. *Mol Cell Endocrinol*. 2007; 275:79–97. [PubMed: 17561338]
69. Perretti M. D'Acquisto, Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. *Nat Rev Immunol*. 2009; 9:62–70. [PubMed: 19104500]

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi: 10.1016/j.bcp.2011.09.009.

Fig. 1.

Molecular characterization and growth rate of different chondrocyte cell lines and primary adult human articular chondrocytes (AHACs). (A) C-28/I2, JJO12, and H-EMC-SS cells, and primary AHAC were cultured in monolayers and analysed for expression of anabolic (*SOX9*, *COL2A1*, *ACAN*) and catabolic (*MMP1*, *MMP13* and *ADAMTS5*) chondrocyte marker genes. Cells underwent chondrocytic stimulation by culturing in serum free conditions, with control (unstimulated) cells kept at 10% serum. The relative units are based on the calculation of $2^{-\Delta\Delta C_t}$, which gives the relative amount of target gene normalized to endogenous control (*GAPDH*) and to the control value set at 1. Fibroblasts were used as negative control. Results are mean $\pm$ SD of 3 independent experiments performed in duplicate; $^{\ddagger}p < 0.05$ vs. C-28/I2 10% FCS and $*p < 0.05$ vs. C-28/I2 0% FCS. (B) C-28/I2, JJO12 and H-EMC-SS cells were cultured in monolayer (serum-free) at different plating densities ($8, 4, 2, 1$ and 0.5×10^4) and assayed for their growth rate using Alamar blue assay. The absorbance (OD; optical density) was read after 24 h, at 570 and 595 nm. Data are mean $\pm$ SD of 3 different experiments performed in triplicate; $*p < 0.05$ vs. C-28/I2.

Fig. 2.

Effect of anabolic and catabolic stimuli on C-28/I2 cells in micromasses (MM). Images in the left panel show MM stained with Alcian blue (AB) to detected glycosaminoglycan (GAG) accumulation after 48 h incubation with TGFβ1 (10 ng/mL; anabolic stimulus) or with IL-1β (20 ng/mL; catabolic stimulus) vs. control (scale bars = 3 mm). Right panel shows a higher-magnification of the boxed areas (scale bars = 100 μm). (B) Accumulation of GAG-rich extracellular matrix *in vitro* was measured by AB staining and normalized to the DNA content (μg/μg). Fibroblasts were used as negative control. (C) Western blotting for total aggrecan after treatment of MM with either IL-1β or TGFβ1 and (D) quantification of pixel density (ratio aggrecan/β-actin). mRNA relative quantification of the chondrocyte

phenotypic marker genes (*SOX9*, *COL2A1*, *ACAN*, *MMP13* and *ADAMTS5*) was assessed by quantitative PCR in (E) C-28/I2 cell line and (F) human primary chondrocytes (AHACs), both in MM incubated with TGF β 1 or IL-1 β . Data (mean $\pm$ SD of 5 experiments in duplicate) are expressed as relative units ($2^{-\Delta\Delta C_t}$). * $p < 0.05$ vs. untreated control.

Fig. 3. Transfectability of C-28/I2 cells and effects of BMP-2 overexpression on gene expression and matrix formation. (A) C-28/I2 cells in monolayer were transfected with a plasmid encoding bone morphogenetic protein (BMP)-2 (pMT7T3-BMP2) or EGFP (control) and then cultured in micromass (MM). Left-hand side: images of C-28/I2 cells in MM stained with Alcian blue (AB) after transfection (bar = 3 mm). Right-hand side: higher-magnification views of the boxed areas (bar = 100 μ m). (B) Relative quantification of the anabolic (*SOX9*, *COL2A1*, *ACAN*) and catabolic (*MMP1* and *ADAMTS5*) marker gene products, as well as BMP-2 mRNA upon transfection with either EGFP or BMP-2 plasmids. Data (mean $\pm$ SD of 5 independent experiments performed in duplicate) are expressed as relative units ($2^{-\Delta\Delta C_t}$). * $p < 0.05$ vs. EGFP transfected (control).

Fig. 4.

Modulation of C-28/I2 in micromasses (MM) by prednisolone and naproxen. C-28/I2 cells in MM were incubated for 48 h with prednisolone (PRED; 10⁻⁸–10⁻⁶ M) or naproxen (NAP; 10⁻⁶–10⁻⁴ M) in the absence or presence of IL-1β (20 ng/mL; catabolic stimulus), and analysed by (A) Alcian blue (AB) staining (values reported as μg AB per μg DNA). Relative expression of anabolic (*SOX9*, *COL2A1* and *ACAN*) and catabolic genes (*MMP1*, *MMP13* and *ADAMTS5*) in presence of IL-1β (20 ng/mL) are shown after (B) PRED and (C) NAP treatments. Data (mean ± SD of 5 independent experiments performed in duplicate) for gene expression are calculated as relative units ($2^{-\Delta\Delta C_t}$). [‡]*p* < 0.05 vs. untreated C-28/I2 (control) and **p* < 0.05 vs. IL-1β treated MM.

Fig. 5.

Effect of prednisolone and naproxen on primary adult human chondrocytes (AHACs). AHACs were treated for 48 h with either prednisolone (PRED 10^{-7} M) or naproxen (NAP 10^{-5} M) in presence of IL-1 β (20 ng/ml), and were subjected to gene expression analysis by quantitative PCR. PRED and NAP suppressed the up-regulation of (D) *MMP13* and (E) *ADAMTS5* genes. PRED also augmented (A) *SOX9* and (C) *ACAN* mRNA expression. Data (mean $\pm$ SD of 3 independent experiments performed in duplicate) are expressed as relative units ($2^{-\Delta\Delta C_t}$). [‡] $p < 0.05$ vs. control AHAC and ^{*} $p < 0.05$ vs. AHACs + IL-1 β .

Table 1

Parameters of the EGFP and BMP-2 transfection.

Parameter	<u>C-28/I2 transfection</u>	
	EGFP	BMP-2
Cell viability	94 ± 3	95 ± 2
Transfection efficiency (%)	28.3 ± 3.1	ND
GAG content (µg AB/µg DNA)	50.2 ± 4.9	125 ± 21 *

Summary of data acquired upon C-28/I2 cells transfection, showing cell viability, transfection efficiency (%), and GAG accumulation measured by Alcian blue (AB) quantification normalized to DNA content (µg/µg). Cells were transfected either with a plasmid encoding bone morphogenetic protein (BMP)-2 (pMT7T3-BMP2) or EGFP. Each data point is the mean ± SD of 5 different experiments performed in duplicate. BMP-2, bone morphogenetic protein-2; EGFP, enhanced green fluorescent protein. ND, not determinate.

* $p < 0.05$ vs. respective EGFP value

Table 2

Effect of anti-inflammatory drugs prednisolone and naproxen on C-28/I2 micromasses in resting conditions.

	PRED (M)			NAP (M)		
	10 ⁻⁸	10 ⁻⁷	10 ⁻⁶	10 ⁻⁶	10 ⁻⁵	10 ⁻⁴
SOX9	1.18 ± 0.1	0.72 ± 0.01	0.71 ± 0.01	0.92 ± 0.04	1.10 ± 0.18	0.98 ± 0.07
COL2A1	1.12 ± 0.2	1.03 ± 0.08	1.13 ± 0.15	1.04 ± 0.08	0.71 ± 0.03 *	0.7 ± 0.02 *
ACAN	1.22 ± 0.2	1.24 ± 0.12	1.10 ± 0.07	0.76 ± 0.01	0.60 ± 0.01 *	0.62 ± 0.01 *
MMP13	0.84 ± 0.02	0.86 ± 0.03	0.90 ± 0.05	1.07 ± 0.03	0.8 ± 0.02	0.76 ± 0.01
ADAMTS5	0.78 ± 0.01	0.95 ± 0.01	0.74 ± 0.01	0.87 ± 0.02	0.95 ± 0.15	1.06 ± 0.3

C-28/I2 cells were grown in micromasses and incubated for 48 h with prednisolone (PRED; 10⁻⁸–10⁻⁶ M) and naproxen (NAP; 10⁻⁶–10⁻⁴ M). Relative expression of anabolic (*SOX9*, *COL2A1*) and *ACAN*) and catabolic genes (*MMP13* and *ADAMTS5*) was measured by real time PCR. *GAPDH* was used as endogenous control. Data are expressed as relative units based on calculation of $2^{-\Delta\Delta Ct}$, which gives the relative amount of target gene normalized to endogenous control (*GAPDH*) and to the control (non-stimulated), set at 1. Data are expressed as means ± SD of 5 independent experiments performed in duplicate.

* $p < 0.05$ vs. untreated C-28/I2 (control).

Table 3

Prostaglandin E₂ (PGE₂) levels in micromass cultures.

	Control	PRED (M)			NAP (M)		
		10 ⁻⁸	10 ⁻⁷	10 ⁻⁶	10 ⁻⁶	10 ⁻⁵	10 ⁻⁴
Basal	120 ± 16	111 ± 7	102 ± 9	112 ± 18	65 ± 20 [*]	56 ± 5 [*]	46 ± 4 [*]
IL-1β	191 ± 20 [‡]	128 ± 23	120 ± 18	121 ± 21	89 ± 5 [*]	88 ± 10 [*]	82 ± 8 [*]

Cell supernatants (serum- and phenol-red free) generated as in Fig. 4 were assayed for PGE₂ concentrations (pg/mL) using a specific enzyme immunoassay (EIA). PRED = prednisolone; NAP = naproxen. Each data point is the mean ± SD of 5 different experiments performed in triplicate.

^{*} *p* <0.05 vs. respective control value.
[‡] *p* <0.05 vs. control/basal value.